NY-FLEXTRADE-SYSTEMS
23.1.2024 14:01:27 CET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems announces a new offering for traders of public equity to plan, manage, and execute equity offerings via their new issue management system, FlexNIMS.
By leveraging this all-in-one solution, global buy-side firms can reduce the time and risk involved with the new issue management process for IPOs, Follow-Ons, and Block Trades by managing the process from the deal evaluation phase, internal interest aggregation and approvals, to compliance checking, and customized individual allocations on deal day. Finally, FlexNIMS can integrate directly with order management systems to book trades all within one user environment.
FlexNIMS provides seamless integration with order management systems, allowing for efficient booking of trades within a single user interface. This comprehensive approach enhances process efficiency and reduces operational risks, directly contributing to our mission of maximizing shareholder value.
Benefits of FlexNIMS include:
- Comprehensive end-to-end ECM workflow for primary market equity deals.
- Calendar-based system encompassing order entry, aggregation, allocation and booking
- Digital order entry and allocation, reducing errors and increasing PM / trader efficiency
- Automatic publication of deal notifications throughout lifecycle of offering
- Sub-allocations according to the user’s internal allocation policy
- Incorporation of internal legal, compliance and oversight policies
- OMS integration to facilitate order booking and finalization
Vijay Kedia, President and CEO at FlexTrade stated: “We are pleased to launch FlexNIMS, the only product of its kind that is seamlessly integrated with a multi-asset EMS, multiple OMS solutions and provides end-to-end automation of Primary Market workflow while reducing risk and connecting all parties in the pre-IPO process. FlexNIMS enables buy-side firms to capture PM interest in equity offerings, aggregate interest across the firm, automate compliance checks, allocation and finally book the trades in their OMSs. The power in this tool derives from the close working relationship and deep insight from our client, Neuberger Berman, and demonstrates our commitment to innovation.”
Rob Arancio, Head of Trading at Neuberger Berman said: “The team at FlexTrade worked to understand the particular needs of our firm. We believe that the technology will benefit our clients as we work more efficiently in pursuit of best pricing and execution. The FlexTrade team has built an end-to-end solution for Equity Capital Markets participation that allows for full straight-through-processing from notification of a deal, right to allocation of shares in the order management system. The system is live on our platform and has successfully completed a number of transactions. “
To learn more about FlexNIMS visit www.flextrade.com or contact sales@flextrade.com.
About FlexTrade
FlexTrade Systems is the global leader in high-performance trading technology, including multi-asset execution and order management systems that span across equities, fixed income, foreign exchange, futures, and options. We’re recognized globally for our innovation, with our flagship product, FlexTRADER® – a pioneering, broker-neutral execution management trading system – leading our suite of transformative solutions.
With a global presence in 45 countries, we work closely with both buy- and sell-side clients. Our team of over 500 dedicated software developers and industry specialists curate powerful, customized trading workflows across multiple asset classes. Our commitment to customer-centric innovation leads to breakthrough solutions that boost trading performance.
About Neuberger Berman
Neuberger Berman, founded in 1939, is a private, independent, employee-owned investment manager. The firm manages a range of strategies—including equity, fixed income, quantitative and multi-asset class, private equity, real estate and hedge funds—on behalf of institutions, advisors and individual investors globally. Neuberger Berman’s investment philosophy is founded on active management, engaged ownership and fundamental research, including industry-leading research into material environmental, social and governance factors. Neuberger Berman is a PRI Leader, a designation awarded to fewer than 1% of investment firms. With offices in 26 countries, the firm’s diverse team has over 2,750 professionals. For nine consecutive years, Neuberger Berman has been named first or second in Pensions & Investments Best Places to Work in Money Management survey (among those with 1,000 employees or more). The firm manages $439 billion in client assets as of September 30, 2023. For more information, please visit our website at www.nb.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123520108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom